Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials

Abstract

In the context of ASCT, achievement of at least VGPR is a simple prognostic factor that has importance in intermediate and high-risk MM and can be informative in more patients than CR.

Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis

“…The iFLC concentration reflects the expansion of the aberrant clone and to some extent the severity of organ involvement. 5,6 Whether cytogenetic aberrations of the plasma cell clone influence prognosis, like they do in patients with multiple myeloma (MM), 7 or predict response to different chemotherapies has to be evaluated in the future. 8,9 Successful treatment of MM with high-dose melphalan (HDM) and autologous hematopoietic cell transplantation (auto-HCT) provided the rationale to establish this approach for selected AL amyloidosis patients, but only about 25% of newly diagnosed patients are eligible for HDM.…”

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

“…[1][2][3][4][5] Three-drug combinations with bortezomib and/or thalidomide or lenalidomide appeared to be superior to most 2-drug combinations of the same agents in patients with newly diagnosed MM. The lenalidomide, bortezomib, and dexamethasone (RVD) regimen and the bortezomib, pegylated liposomal doxorubicin (PLD), and dexamethasone (VDD) regimens are among the most active in this setting, producing high rates of very good partial response (VGPR), complete response (CR), and near CR (nCR).…”

Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma

“…PFS2, the time from first treatment to second relapse, takes account of tumour resistance induced by the first line of treatment, and to date studies have shown it is prolonged in association with PFS (Palumbo et al, 2014b;Tacchetti et al, 2014), but it has not yet been validated as a surrogate for OS, and still takes years of follow up to report mature data. By contrast, recent ASCT trials have shown an association between the depth of response and overall survival (Harousseau et al, 2009;Lahuerta et al, 2008) and this is particularly the case for prolonged (>3 years) complete response .…”